181 related articles for article (PubMed ID: 1326346)
1. Hetrazepine PAF antagonists.
Ikegami K; Meade CJ; Heuer HO; Birke F
J Lipid Mediat; 1992; 5(2):177-82. PubMed ID: 1326346
[TBL] [Abstract][Full Text] [Related]
2. [Platelet-activating factor (PAF) antagonists].
Terasawa M
Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):379-87. PubMed ID: 1850862
[No Abstract] [Full Text] [Related]
3. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
Floch A; Tahraoui L; Sedivy P; Cavero I
J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
5. Specific binding sites of platelet activating factor on the intact bovine cerebral microvascular endothelial cells and antagonism of drugs.
Sun DX; Rui YC; Zeng GQ; Zhu J; Shen YA
Zhongguo Yao Li Xue Bao; 1992 Jul; 13(4):326-9. PubMed ID: 1333718
[TBL] [Abstract][Full Text] [Related]
6. [Characterization of platelet-activating factor (PAF)-receptors in neutrophilic and eosinophilic granulocytes].
Ukena D; Dent G; Chanez P; Barnes PJ; Sybrecht GW
Pneumologie; 1990 Feb; 44 Suppl 1():531-2. PubMed ID: 2164200
[TBL] [Abstract][Full Text] [Related]
7. Intracellular mechanisms of hydrogen peroxide-mediated neutrophil adherence to cultured human endothelial cells.
Okayama N; Coe L; Oshima T; Itoh M; Alexander JS
Microvasc Res; 1999 Mar; 57(2):63-74. PubMed ID: 10049654
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
11. Endothelial cell-associated platelet-activating factor primes neutrophils for enhanced superoxide production and arachidonic acid release during adhesion to but not transmigration across IL-1 beta-treated endothelial monolayers.
Hill ME; Bird IN; Daniels RH; Elmore MA; Finnen MJ
J Immunol; 1994 Oct; 153(8):3673-83. PubMed ID: 7930587
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
13. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
Yue TL; Gleason MM; Gu JL; Lysko PG; Hallenbeck J; Feuerstein G
J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
[TBL] [Abstract][Full Text] [Related]
14. Characterization of receptors for platelet-activating factor in guinea pig lung membranes.
Gomez J; Bloom JW; Yamamura HI; Halonen M
Am J Respir Cell Mol Biol; 1990 Sep; 3(3):259-64. PubMed ID: 2167700
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
[TBL] [Abstract][Full Text] [Related]
16. Degree of platelet activating factor-induced neutrophil migration is dependent upon the molecular species.
Carolan EJ; Casale TB
J Immunol; 1990 Oct; 145(8):2561-5. PubMed ID: 2170519
[TBL] [Abstract][Full Text] [Related]
17. Platelet-activating factor induction of secreted phosphatase activity in Trypanosoma cruzi.
Rodrigues CO; Dutra PM; Barros FS; Souto-Padrón T; Meyer-Fernandes JR; Lopes AH
Biochem Biophys Res Commun; 1999 Dec; 266(1):36-42. PubMed ID: 10581161
[TBL] [Abstract][Full Text] [Related]
18. Regulation of platelet-activating factor (PAF) synthesis and PAF-mediated neutrophil adhesion to endothelial cells activated by thrombin.
Carveth HJ; Shaddy RE; Whatley RE; McIntyre TM; Prescott SM; Zimmerman GA
Semin Thromb Hemost; 1992 Jan; 18(1):126-34. PubMed ID: 1315452
[No Abstract] [Full Text] [Related]
19. Structure-activity relationships and effects of platelet-activating factor antagonists in the hetrazepine series.
Weber KH; Heuer H
Int Arch Allergy Appl Immunol; 1989; 88(1-2):82-7. PubMed ID: 2540098
[TBL] [Abstract][Full Text] [Related]
20. Mechanism and regulation of neutrophil priming by platelet-activating factor.
Gay JC
J Cell Physiol; 1993 Jul; 156(1):189-97. PubMed ID: 8391006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
